Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Cancer
NCT00020267 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00020267 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Cancer |
| Official title | Phase I Randomized Study of MAGE-12 Peptide Vaccine in Patients With Refractory Metastatic Cancer Expressing MAGE-12 Antigen |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer, Ovarian Sarcoma, Melanoma, Colon Cancer, Rectal Cancer, Breast Cancer, Eye Cancer and 1 more |
| Intervention type | Drug |
| Interventions | interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51 |
| Start date | Jul 1, 2000 |
| First posted | Mar 6, 2007 |
| Last update posted | Mar 4, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: